Navigation Links
Synthetic Biologics to Host Multiple Sclerosis-Estriol Investor Day in New York City on June 25, 2013
Date:6/13/2013

ROCKVILLE, Md., June 13, 2013 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of biologics focused on the prevention and treatment of serious infectious diseases, announced today that it will host a Multiple Sclerosis-Estriol Investor Day on Tuesday, June 25, 2013 from 9:00 a.m. to 11:00 a.m. at the InterContinental New York Barclay Hotel in New York City. This event will be accessible via a live webcast through the following internet link, https://viavid.webcasts.com/starthere.jsp?ei=1018556

Keynote speaker, Rhonda R. Voskuhl, M.D., will join Synthetic Biologics' executive management remotely for the presentations. Dr. Voskuhl is Professor, Department of Neurology, Jack H. Skirball Chair in Multiple Sclerosis Research and Director, Multiple Sclerosis Program at UCLA School of Medicine, and the lead investigator of the Phase II clinical trial evaluating the Company's oral estriol product candidate, Trimesta™, for the treatment of relapsing-remitting multiple sclerosis (MS). An overview of MS and the current market, as well as the history of estriol and its role in the treatment of MS will be discussed.

About Synthetic Biologics, Inc.

Synthetic Biologics, Inc. (NYSE MKT: SYN) is a biotechnology company focused on the development of biologics for the prevention and treatment of serious infectious diseases. The Company is developing an oral enzyme for the prevention of C. difficile infections, and a series of monoclonal antibody therapies for the treatment of Pertussis and Acinetobacter infections. In addition, the Company is developing a drug candidate for the treatment of relapsing-remitting multiple sclerosis and cognitive dysfunction in multiple sclerosis. For more information, please visit Synthetic Biologics' website at www.syntheticbiologics.com.

To download Synthetic Biologics' investor relations mobile device app, which allows users access to the Company's SEC documents, press releases and events, please click on the following links to download the IRapp on your iPhone and iPad or your Android mobile device.


'/>"/>
SOURCE Synthetic Biologics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Research Team Publishes New Methods for Synthetic Generation of Influenza Vaccines
2. Synthetic Biologics Reports First Quarter 2013 Financial Results
3. Peripheral Vascular Devices Market (Peripheral Vascular Stents, PTA Balloon Catheters, Guidewires, IVC Filters, Atherectomy, Chronic Total Occlusion, Embolic Protection Devices, Synthetic Surgical Grafts, Aortic Stents) - Global Industry Analysis, S
4. Details of New Synthetic Vaccine for Emerging H7N9 Threat Revealed at BIO International Convention in Chicago, April 22-25
5. Synthetic Biologics Reports Year End 2012 Financial Results
6. What Will Thermo Fisher Scientific and Life Technologies $14 billion Merger hold for the Top Ten Suppliers of Synthetic Biology Technology and DNA Sequencing Landscape?
7. Synthetic Biologics to Present at the 25th Annual ROTH Conference
8. Synthetic Biologics Reports that Flupirtine Sublicensee, Meda AB, to Initiate Phase II Fibromyalgia Clinical Trial in U.S.
9. Inovios Synthetic Flu Vaccine Doubles Rate of Elderly Subjects Displaying Protective Immune Responses
10. Synthetic Biologics Closes Deal for Acquisition of C. difficile Infectious Disease Program
11. Inovio Expands Synthetic Vaccine Intellectual Property License With University of Pennsylvania
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)... , Feb. 17, 2017   Risperdal lawsuits involving ... allegedly associated with use of the atypical antipsychotic medication ... Court of Common Pleas, where the state,s ... program. According to a notice posted on the ... a meeting on March 9, 2017 at 11:00 a.m. ...
(Date:2/17/2017)...   FormFast , the leader in electronic forms ... Engage , one of the largest MEDITECH partners ... will serve as the forms automation and electronic signature ... .  FormFast is a MEDITECH collaborative ... enhance the electronic health record. FormFast,s technology bridges clinical ...
(Date:2/17/2017)... Feb. 17, 2017  BioDigital, Inc., creators of ... of their 3D body mapping technology with eClinicalWorks, ... new integration will be used to capture and ... of the human body. BioDigital pilots show using ... while also increasing the precision of clinical annotations ...
Breaking Medicine Technology:
(Date:2/18/2017)... Waltham, Massachusetts (PRWEB) , ... February 17, 2017 ... ... be the leading source of disruptive innovation in the industry, according to the ... Insights Reports are based on surveys of the NEJM Catalyst Insights Council, a ...
(Date:2/18/2017)... MANDEVILLE, La. (PRWEB) , ... February 18, 2017 ... ... Network released today provides the latest information and contact points to easily connect ... including home care, assisted living, and elder-care funding. It also conveys material on ...
(Date:2/17/2017)... ... 2017 , ... For the first time, International Scholarship and ... floor for the 2017 HIMSS Conference & Exhibition at the Orange ... than 40,000 healthcare industry professionals are expected at the conference, where they will ...
(Date:2/17/2017)... Texas (PRWEB) , ... February 17, 2017 , ... ... 8.0 at the HIMSS17 Conference & Exhibition in Orlando, Fla., February 19-23. Visitors ... version of the most widely used electronic patient signatures solution in healthcare ...
(Date:2/17/2017)... ... February 17, 2017 , ... Cancer diagnostics workflow solution ... February 20 – 22 in San Francisco. As part of the Tri-Conference expo, ... pathology workflow solution, as well as its new precision medicine platform, “Crosswalk Insight: ...
Breaking Medicine News(10 mins):